WP
MIRM icon

Woodline Partners’s Mirum Pharmaceuticals MIRM Stock Holding History

Woodline Partners’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.5M Hold
567,894
– – 0.21% 127
2026
Q1 		$52.5M Hold
567,894
– – 0.2% 129
2025
Q4 		$44.9M Hold
567,894
– – 0.17% 154
2025
Q3 		$41.6M Hold
567,894
– – 0.2% 143
2025
Q2 		$28.9M Buy
567,894
+1,623
+0.3% +$72.3K 0.15% 203
2025
Q1 		$25.5M Buy
566,271
+161,867
+40% +$7.63M 0.17% 181
2024
Q4 		$16.7M Buy
404,404
+73,399
+22% +$3.06M 0.11% 245
2024
Q3 		$12.9M Buy
331,005
+127,285
+62% +$5.08M 0.11% 256
2024
Q2 		$6.97M Sell
203,720
-29,547
-13% -$775K 0.07% 297
2024
Q1 		$5.86M Sell
233,267
-19,996
-8% -$550K 0.05% 341
2023
Q4 		$7.48M Sell
253,263
-199,444
-44% -$6.04M 0.08% 262
2023
Q3 		$14.3M Buy
452,707
+124,889
+38% +$3.42M 0.17% 172
2023
Q2 		$8.48M Sell
327,818
-196,062
-37% -$5.21M 0.1% 226
2023
Q1 		$12.6M Buy
523,880
+163,288
+45% +$3.72M 0.17% 171
2022
Q4 		$7.03M Buy
360,592
+3,640
+1% +$72K 0.09% 267
2022
Q3 		$7.5M Buy
+356,952
New +$8.59M 0.1% 233

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Woodline Partners's MIRM Position: Q2 2026 in Review

Woodline Partners held its Mirum Pharmaceuticals (MIRM) position steady in Q2 2026 at 567,894 shares worth $66.5M. The position accounts for 0.21% of the portfolio, ranked #127.

Woodline Partners first reported a position in MIRM in Q3 2022 and has held it in 16 quarters since. 328 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Woodline Partners held 567,894 shares of Mirum Pharmaceuticals worth $66.5M as of Q2 2026.
  • Woodline Partners left its Mirum Pharmaceuticals share count unchanged in Q2 2026.
  • Mirum Pharmaceuticals made up 0.21% of Woodline Partners's portfolio in Q2 2026, its #127 holding.
  • Woodline Partners first reported a position in Mirum Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • 328 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.